Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.32 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4618656 | 0.81 | TDP1 (0.43) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL9098045 | 0.78 | TDP1 (0.37) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL10778722 | 0.78 | TDP1 (0.37) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL606592 | 0.78 | TDP1 (0.37) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL606593 | 0.78 | TDP1 (0.37) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL1604267 | 0.78 | TDP1 (0.50) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL13761133 | 0.78 | TDP1 (0.50) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL4756190 | 0.78 | TDP1 (0.50) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL20838339 | 0.77 | TDP1 (0.40) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| Ethane SCHEMBL8713495 | 0.76 | TDP1 (0.36) | TDP1CHRM1AKR1A1CHRM3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269943-A1 | RADIOLABELED ANNEXINS | UNIVERSITY OF WASHINGTON (US) | 2011-11-03 | — | — | US | disclosed |
| US-7744853-B2 | Radiolabeled annexins | PONIARD PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7115248-B2 | Radiolabeled annexins | NEORX CORPORATION (US) | 2006-10-03 | — | — | US | disclosed |
| US-20060029545-A1 | Radiolabeled annexins | NEORX CORPORATION, REGENTS OF THE UNIVERSITY OF MICHIGAN | 2006-02-09 | — | — | US | disclosed |
| US-20050036948-A1 | Radiolabeled annexins | NEORX CORPORATION (US) | 2005-02-17 | — | — | US | disclosed |
| EP-1486509-A2 | Radiolabeled annexin-galactose cluster conjugates | NEORX CORPORATION (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-0799050-B1 | RADIOLABELED ANNEXIN-GALACTOSE CLUSTER CONJUGATES | NEORX CORP (US) | 2004-08-11 | — | — | EP | disclosed |
| EP-1426062-A2 | Radiolabeled annexins | NEORX CORPORATION (US) | 2004-06-09 | — | — | EP | disclosed |
| EP-0918547-B1 | RADIOLABELED ANNEXINS | NEORX CORP (US) | 2004-03-10 | — | — | EP | disclosed |
| US-20030220233-A1 | Radiolabeled annexins | NEORX CORPORATION | 2003-11-27 | — | — | US | disclosed |
| EP-0918547-A2 | RADIOLABELED ANNEXINS | NEORX CORPORATION (US) | 1999-06-02 | — | — | EP | disclosed |
| US-5886143-A | Hepatic-directed compounds and reagents for preparation thereof | NEORX CORPORATION (US) | 1999-03-23 | — | — | US | disclosed |
| EP-0799050-A4 | RADIOLABELED ANNEXIN-GALACTOSE CLUSTER CONJUGATES | NEORX CORP (US) | 1998-06-03 | — | — | EP | disclosed |
| WO-1998004294-A2 | RADIOLABELED ANNEXINS | NEORX CORPORATION (US) | 1998-02-05 | — | — | WO | disclosed |
| EP-0799050-A1 | RADIOLABELED ANNEXIN-GALACTOSE CLUSTER CONJUGATES | NEORX CORPORATION (US) | 1997-10-08 | — | — | EP | disclosed |
| EP-0794788-A1 | HEPATIC-DIRECTED COMPOUNDS AND REAGENTS FOR PREPARATION THEREOF | NEORX CORPORATION (US) | 1997-09-17 | — | — | EP | disclosed |
| EP-0759913-A1 | AROMATIC AMINE SUBSTITUTED BRIDGED NITROGEN AND SULFUR DONOR ATOM LIGANDS FOR IMAGING | NEORX CORPORATION (US) | 1997-03-05 | — | — | EP | disclosed |
| WO-1996017613-A1 | HEPATIC-DIRECTED COMPOUNDS AND REAGENTS FOR PREPARATION THEREOF | NEORX CORPORATION (US) | 1996-06-13 | — | — | WO | disclosed |
| WO-1996017618-A1 | RADIOLABELED ANNEXIN-GALACTOSE CLUSTER CONJUGATES | NEORX CORPORATION (US) | 1996-06-13 | — | — | WO | disclosed |
| WO-1995032192-A1 | AROMATIC AMINE SUBSTITUTED BRIDGED NITROGEN AND SULFUR DONOR ATOM LIGANDS FOR IMAGING | NEORX CORPORATION (US) | 1995-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060029545-A1 | Radiolabeled annexins | ANXA11, ANXA1, ANXA3 | TDP1 1659/4885CHRM1 4434/4885AKR1A1 3551/4885 |
| US-20050036948-A1 | Radiolabeled annexins | ANXA11, ANXA1, ANXA3 | TDP1 1659/4885CHRM1 4434/4885AKR1A1 3551/4885 |
| US-20110269943-A1 | RADIOLABELED ANNEXINS | ANXA11, ANXA1, ANXA3 | TDP1 1659/4885CHRM1 4434/4885AKR1A1 3551/4885 |
| US-20030220233-A1 | Radiolabeled annexins | ANXA11, ANXA1, ANXA3 | TDP1 1659/4885CHRM1 4434/4885AKR1A1 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.